Brandicourt’s Message To Sanofi Investors: Grow, Build, Explore Options
This article was originally published in The Pink Sheet Daily
CEO Olivier Brandicourt's multi-pronged strategy involves defending in core areas like diabetes, vaccines and rare diseases, building in consumer healthcare, oncology and multiple sclerosis and reviewing strategic alternatives in other areas, including animal health.
You may also be interested in...
Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.